OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado

Detalhes bibliográficos
Autor(a) principal: Souza, Fátima Cleonice de
Data de Publicação: 2017
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional PUCRS
Texto Completo: http://hdl.handle.net/10923/10800
Resumo: Introduction: Acute respiratory tract infections (ARTI) are one of the most important causes of mortality in children under 5 years old. In developed countries ARTI account for 20% of emergency consultations and 75% of antibiotic prescriptions. Children in attending day care are more prone to recurrence of respiratory infections. Bacterial immunostimulants, resulting from the chemical lysis of microorganisms associated with most respiratory tract infections, have been propagated as possibly useful intervention for prevention of recurrent respiratory infections. Objective: To analyze the effectiveness of OM-85 Broncho-vaxom (OM-85 BV) on the prevention of upper respiratory tract infections in healthy children attending preschool during the 6-month period. Methods: A randomized, double-blind, placebo controlled study was conducted in 54 healthy children aged between 6 months to 5 years attending in the School for Early Childhood Education between the months of April and September. Use of OM-85 BV for 3 months and observed for a further 3 months the following outcomes: upper respiratory tract infection, bronchopneumonia, other infections, use of antibiotics, emergency consultations, need for hospital stay, side effects of the medication. Results: Of the 54 children included, 57% were male. All completed the study and there were no significant differences between the groups. Of the 27 patients in group OM-85 BV, 19 (70,4%), attending daycare full-time and 16 (64,85%) half period, morning or evening. Breastfeeding was exclusive until 6 months in 6 patients (22,2%) on the OM-85 BV group and in 7 (25,9%) patients in the control group. Family history of smoking was positive in 11 (40,7%) patients in the OM-85 BV group and in 13 (48,1%) patients in the control group. Regarding the number of respiratory infections, the mean in the OM-85 BV group in the first 3 months was 0,92± 0,87 and in the placebo group was 0,74± 1,02 and in the 6 months was 1,62± 1,47 and 1,03±1,34, respectively. Antibiotic was used in 10 (37%) children of the OM-85BV group in the 3 months of treatment and in 13 (48,1%) of the placebo group, and in the 6 months of follow-up the use was 48,1% in both groups. The mean number of hospitalizations was very low in the period of the study. The mean number of emergency visits during the first 3 months was 0,81±1,21 in the OM-85 BV group and 1,29±1,48 in the placebo group and at 6 months was 1,77±1,80 in the OM-85 BV group and 2,03±1,76 in the placebo group. Conclusions: OM-85 BV was not effective as an intervention in daycare children with no history of IRR. No statistically significant difference was observed between the groups in the use of antibiotics, emergency consultations and hospitalizations.
id PUCR_b9f435106f02a95ab299f5bf351796b7
oai_identifier_str oai:repositorio.pucrs.br:10923/10800
network_acronym_str PUCR
network_name_str Repositório Institucional PUCRS
repository_id_str 2753
spelling Souza, Fátima Cleonice dePinto, Leonardo Araújo2017-10-14T12:01:24Z2017-10-14T12:01:24Z2017http://hdl.handle.net/10923/10800Introduction: Acute respiratory tract infections (ARTI) are one of the most important causes of mortality in children under 5 years old. In developed countries ARTI account for 20% of emergency consultations and 75% of antibiotic prescriptions. Children in attending day care are more prone to recurrence of respiratory infections. Bacterial immunostimulants, resulting from the chemical lysis of microorganisms associated with most respiratory tract infections, have been propagated as possibly useful intervention for prevention of recurrent respiratory infections. Objective: To analyze the effectiveness of OM-85 Broncho-vaxom (OM-85 BV) on the prevention of upper respiratory tract infections in healthy children attending preschool during the 6-month period. Methods: A randomized, double-blind, placebo controlled study was conducted in 54 healthy children aged between 6 months to 5 years attending in the School for Early Childhood Education between the months of April and September. Use of OM-85 BV for 3 months and observed for a further 3 months the following outcomes: upper respiratory tract infection, bronchopneumonia, other infections, use of antibiotics, emergency consultations, need for hospital stay, side effects of the medication. Results: Of the 54 children included, 57% were male. All completed the study and there were no significant differences between the groups. Of the 27 patients in group OM-85 BV, 19 (70,4%), attending daycare full-time and 16 (64,85%) half period, morning or evening. Breastfeeding was exclusive until 6 months in 6 patients (22,2%) on the OM-85 BV group and in 7 (25,9%) patients in the control group. Family history of smoking was positive in 11 (40,7%) patients in the OM-85 BV group and in 13 (48,1%) patients in the control group. Regarding the number of respiratory infections, the mean in the OM-85 BV group in the first 3 months was 0,92± 0,87 and in the placebo group was 0,74± 1,02 and in the 6 months was 1,62± 1,47 and 1,03±1,34, respectively. Antibiotic was used in 10 (37%) children of the OM-85BV group in the 3 months of treatment and in 13 (48,1%) of the placebo group, and in the 6 months of follow-up the use was 48,1% in both groups. The mean number of hospitalizations was very low in the period of the study. The mean number of emergency visits during the first 3 months was 0,81±1,21 in the OM-85 BV group and 1,29±1,48 in the placebo group and at 6 months was 1,77±1,80 in the OM-85 BV group and 2,03±1,76 in the placebo group. Conclusions: OM-85 BV was not effective as an intervention in daycare children with no history of IRR. No statistically significant difference was observed between the groups in the use of antibiotics, emergency consultations and hospitalizations.Introdução: As infecções agudas do trato respiratório estão entre as causas mais importantes de mortalidade na faixa etária abaixo dos 5 anos, sendo, em países desenvolvidos, responsáveis por 20% das consultas nas emergências e 75% das prescrições de antibióticos. Crianças que frequentam creche são mais propensas à recorrência das infecções respiratórias. Os imunoestimulantes bacterianos, resultantes da lise química de microrganismos associados com a maioria das infecções respiratórias, têm sido propagados como intervenção possivelmente útil para a prevenção das infecções respiratórias recorrentes (IRR). Objetivo: Analisar a eficácia do OM-85 Broncho Vaxom (OM-85 BV) na prevenção de infecções respiratórias do trato respiratório superior em crianças hígidas que frequentam pré-escola, durante o período de 6 meses. Métodos: Desenvolveu-se um estudo randomizado duplo cego placebo controlado em 54 crianças previamente hígidas, com idade entre 6 meses e 5 anos, que frequentavam a Escola de Educação Infantil entre os meses de abril e setembro. Usado OM-85 BV por 3 meses e observado por mais 3 meses os seguintes desfechos: presença de infecção do trato respiratório superior, broncopneumonia, outras infecções, uso de antibióticos, consultas na emergência, necessidade de internação hospitalar, dias de ausência à creche e efeitos colaterais da medicação. Resultados: Das 54 crianças incluídas, 57% eram do sexo masculino. Todos completaram o estudo e não houve diferenças significativas entre os grupos. Dos 27 pacientes do grupo OM-85 BV, 19 (70,4%), frequentavam a creche em turno integral e dos 27 pacientes do grupo controle, 16 (64,8%). O aleitamento materno, foi exclusivo até o 6º mês em 6 (22,2%) pacientes do grupo OM-85 BV em 7 (25,9%) pacientes do grupo controle. Quanto à história familiar de fumo, foi positiva em 11 (40,7%) pacientes do grupo OM-85 BV e em 13 (48,1%) pacientes do grupo controle. Em relação ao número de infecções respiratórias, a média no grupo OM-85 BV nos primeiros 3 meses foi 0,92±0,87 e no grupo placebo foi 0,74±1,02 e nos 6 meses foi 1,62±1,47 e 1,03±1,34, respectivamente. Antibiótico foi usado em 10 (37%) crianças do grupo OM-85BV nos 3 meses de tratamento e em 13 (48,1%) do grupo placebo, já nos 6 meses de acompanhamento o uso foi de 48,1% nos dois grupos. A média de internações foi muito baixa no período estudado. A média de consultas na emergência nos primeiros 3 meses foi de 0,81±1,21 no grupo OM-85 BV e 1,29±1,48 no grupo placebo e nos 6 meses foi de 1,77±1,80 no grupo OM-85 BV e 2,03±1,76 no grupo placebo. Conclusões: OM-85 BV não foi eficaz como intervenção em crianças que frequentam creche, sem história de IRR. Não houve diferença estatisticamente significativa no uso de antibióticos, consultas na emergência e internações hospitalaresMade available in DSpace on 2017-10-14T12:01:24Z (GMT). No. of bitstreams: 1 000486113-Texto+Confidencial-0.pdf: 458843 bytes, checksum: 0d967a19c295f0b396c7b9f788dc0c8a (MD5) Previous issue date: 2017Pontifícia Universidade Católica do Rio Grande do SulPorto AlegreINFECÇÕES RESPIRATÓRIASDOENÇAS RESPIRATÓRIASPEDIATRIAMEDICINAOM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controladoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisPontifícia Universidade Católica do Rio Grande do SulEscola de MedicinaPrograma de Pós-Graduação em Medicina e Ciências da SaúdeDoutorado2017info:eu-repo/semantics/openAccessporreponame:Repositório Institucional PUCRSinstname:Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)instacron:PUC_RSORIGINALTES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdfTES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdfTexto completoapplication/pdf880598https://repositorio.pucrs.br//bitstream/10923/10800/4/TES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf689eb5cf56995aa9a6100e6827f43c4cMD54TEXT000486113-Texto+Confidencial-0.pdf.txt000486113-Texto+Confidencial-0.pdf.txtExtracted texttext/plain1470https://repositorio.pucrs.br//bitstream/10923/10800/3/000486113-Texto%2BConfidencial-0.pdf.txte939fb428ce69ae88da91bbe7ce1e78aMD53TES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf.txtTES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf.txtExtracted texttext/plain82261https://repositorio.pucrs.br//bitstream/10923/10800/5/TES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf.txt936b81ce4db7fdda026677c53ecae4ddMD55LICENSElicense.txttext/plain601https://repositorio.pucrs.br//bitstream/10923/10800/2/license.txt3d470ad030ca6782c9f44a1fb7650ec0MD5210923/108002022-10-06 18:00:12.882oai:repositorio.pucrs.br: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Repositório InstitucionalPRIhttp://repositorio.pucrs.br/oai/request?verb=Identifyopendoar:27532022-10-06T21:00:12Repositório Institucional PUCRS - Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)false
dc.title.pt_BR.fl_str_mv OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
title OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
spellingShingle OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
Souza, Fátima Cleonice de
INFECÇÕES RESPIRATÓRIAS
DOENÇAS RESPIRATÓRIAS
PEDIATRIA
MEDICINA
title_short OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
title_full OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
title_fullStr OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
title_full_unstemmed OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
title_sort OM-85BV na prevenção de infecções recorrentes de vias aéreas: um estudo randomizado, duplo cego, placebo controlado
author Souza, Fátima Cleonice de
author_facet Souza, Fátima Cleonice de
author_role author
dc.contributor.author.fl_str_mv Souza, Fátima Cleonice de
dc.contributor.advisor1.fl_str_mv Pinto, Leonardo Araújo
contributor_str_mv Pinto, Leonardo Araújo
dc.subject.por.fl_str_mv INFECÇÕES RESPIRATÓRIAS
DOENÇAS RESPIRATÓRIAS
PEDIATRIA
MEDICINA
topic INFECÇÕES RESPIRATÓRIAS
DOENÇAS RESPIRATÓRIAS
PEDIATRIA
MEDICINA
description Introduction: Acute respiratory tract infections (ARTI) are one of the most important causes of mortality in children under 5 years old. In developed countries ARTI account for 20% of emergency consultations and 75% of antibiotic prescriptions. Children in attending day care are more prone to recurrence of respiratory infections. Bacterial immunostimulants, resulting from the chemical lysis of microorganisms associated with most respiratory tract infections, have been propagated as possibly useful intervention for prevention of recurrent respiratory infections. Objective: To analyze the effectiveness of OM-85 Broncho-vaxom (OM-85 BV) on the prevention of upper respiratory tract infections in healthy children attending preschool during the 6-month period. Methods: A randomized, double-blind, placebo controlled study was conducted in 54 healthy children aged between 6 months to 5 years attending in the School for Early Childhood Education between the months of April and September. Use of OM-85 BV for 3 months and observed for a further 3 months the following outcomes: upper respiratory tract infection, bronchopneumonia, other infections, use of antibiotics, emergency consultations, need for hospital stay, side effects of the medication. Results: Of the 54 children included, 57% were male. All completed the study and there were no significant differences between the groups. Of the 27 patients in group OM-85 BV, 19 (70,4%), attending daycare full-time and 16 (64,85%) half period, morning or evening. Breastfeeding was exclusive until 6 months in 6 patients (22,2%) on the OM-85 BV group and in 7 (25,9%) patients in the control group. Family history of smoking was positive in 11 (40,7%) patients in the OM-85 BV group and in 13 (48,1%) patients in the control group. Regarding the number of respiratory infections, the mean in the OM-85 BV group in the first 3 months was 0,92± 0,87 and in the placebo group was 0,74± 1,02 and in the 6 months was 1,62± 1,47 and 1,03±1,34, respectively. Antibiotic was used in 10 (37%) children of the OM-85BV group in the 3 months of treatment and in 13 (48,1%) of the placebo group, and in the 6 months of follow-up the use was 48,1% in both groups. The mean number of hospitalizations was very low in the period of the study. The mean number of emergency visits during the first 3 months was 0,81±1,21 in the OM-85 BV group and 1,29±1,48 in the placebo group and at 6 months was 1,77±1,80 in the OM-85 BV group and 2,03±1,76 in the placebo group. Conclusions: OM-85 BV was not effective as an intervention in daycare children with no history of IRR. No statistically significant difference was observed between the groups in the use of antibiotics, emergency consultations and hospitalizations.
publishDate 2017
dc.date.accessioned.fl_str_mv 2017-10-14T12:01:24Z
dc.date.available.fl_str_mv 2017-10-14T12:01:24Z
dc.date.issued.fl_str_mv 2017
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10923/10800
url http://hdl.handle.net/10923/10800
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre
publisher.none.fl_str_mv Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre
dc.source.none.fl_str_mv reponame:Repositório Institucional PUCRS
instname:Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
instacron:PUC_RS
instname_str Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
instacron_str PUC_RS
institution PUC_RS
reponame_str Repositório Institucional PUCRS
collection Repositório Institucional PUCRS
bitstream.url.fl_str_mv https://repositorio.pucrs.br//bitstream/10923/10800/4/TES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf
https://repositorio.pucrs.br//bitstream/10923/10800/3/000486113-Texto%2BConfidencial-0.pdf.txt
https://repositorio.pucrs.br//bitstream/10923/10800/5/TES_FATIMA_CLEONICE_DE_SOUZA_COMPLETO.pdf.txt
https://repositorio.pucrs.br//bitstream/10923/10800/2/license.txt
bitstream.checksum.fl_str_mv 689eb5cf56995aa9a6100e6827f43c4c
e939fb428ce69ae88da91bbe7ce1e78a
936b81ce4db7fdda026677c53ecae4dd
3d470ad030ca6782c9f44a1fb7650ec0
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional PUCRS - Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
repository.mail.fl_str_mv
_version_ 1747679172573003776